LLY Eli Lilly and Co
- 831.760
- -0.830-0.10%
- 831.070
- -0.690-0.08%
Eli Lilly and Co News
Eli Lilly Snaps Six Straight Days of Gains, Trades in the Red
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower.At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE
Form 144 | Eli Lilly and Co(LLY.US) 10% Stockholder Proposes to Sell 166.52 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 5, $Eli Lilly and Co(LLY.US)$ 10% Stockholder LILLY ENDOWMENT INC intends to sell 200K shares of its common stock on Jun 5, with a total market value of approximately $166.
Eli Lilly on Track for Record High Close -- Data Talk
Eli Lilly and Company (LLY) is currently at $836.00, up $3.41 or 0.41% --Would be new all-time high (Based on available data back to July 18, 1972) --Currently up eight of the past nine days --Curr
LifeMD Gains as KeyBanc Issues Bullish View on Weight Loss Program
Biogen Favored at RBC as Eli Lilly Awaits FDA AdCom on Alzheimer's Drug
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Eli Lilly And Company
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target to $940 from $930, re
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
Britain's medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co's (NYSE:LLY) weight-loss drug Mounjaro for certain patients with obesi
New Alphabet CFO Will Help Quell 'Uncertainty': Analyst
Express News | Eli Lilly Shares Down 1.3% After Co's CFO to Depart, Join Alphabet
Alphabet Names a New CFO. It Took Almost a Year. -- Barrons.com
By Eric J. Savitz Alphabet said Anat Ashkenazi will become its chief financial officer of both the parent company and its Google unit, taking the place of Ruth Porat. The shift takes effect July 31.
Google Parent Alphabet Poaches Eli Lilly Finance Chief Ashkenazi
Google parent Alphabet has named Anat Ashkenazi as its next finance chief officer, plucking the executive from drugmaker Eli Lilly.
Eli Lilly and Co (LLY.US) is too strong, NASH concept stocks suffer a painful blow.
According to the Zhitong Finance app, the stock prices of drug developers for non-alcoholic steatohepatitis (NASH), a type of liver disease, fell on Wednesday. The reason is that earlier detailed data from Eli Lilly and Co's (LLY.US) weight loss drug, Tirzepatide, showed its potential in treating NASH. The data shows that Madrigal Pharmaceuticals (MDGL.US) fell more than 13%. It is understood that earlier this year, the company received FDA approval for its main asset, Rezafungin, used for NASH (also known as metabolic dysfunction-associated fatty liver disease, MASH).
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating
BofA Securities analyst Geoff Meacham maintains $Eli Lilly and Co(LLY.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 49.4% and a total average return of 3.0% over
Jobs Data, Alphabet's New CFO, HPE Earnings: Three Things
Dow Inc. futures are rising, and despite weak U.S. indicators, optimism is gradually spreading in the U.S. stock market.
Dow Futures, S&P500 and Nasdaq 100 all rose in the US stock index futures market. It is the third day of June market since this week, but there have been a series of weak US economic indicators announced before that. Even the ADP employment statistics just released show a cooling off of employment. Although it reinforces concerns over the future of the economy, it also confirms the expectation of a Fed rate cut later this year.
Eli Lilly and Co (LLY.US) CFO Ashkenazi announced his resignation and will become the financial head of Alphabet (GOOGL.US) from July 31.
According to the Zhītōng Cáijīng APP, Eli Lilly and Co (LLY.US) recently announced that its Chief Financial Officer, Anat Ashkenazi, has decided to leave the company to pursue career opportunities outside of the pharmaceutical industry. Ashkenazi had a career spanning over twenty years at Eli Lilly, during which she held not only the position of CFO but also served as Senior Vice President of Lilly Research Laboratories and CFO. Eli Lilly stated that it is actively searching for suitable candidates internally and externally to succeed Ashkenazi's position, to ensure stability in the financial leadership.
Correction to Alphabet CFO Article
Google parent Alphabet poached Eli Lilly Finance Chief Anat Ashkenazi. "Google Poaches Eli Lilly Finance Chief Ashkenazi," at 8:11 a.m. ET, and "Google Poaches Eli Lilly Finance Chief Ashkenazi -- Upd
Who Is Anat Ashkenazi, the Eli Lilly Veteran Becoming Google's Next CFO?
By Emily Bary Lilly shares have jumped 300% in the time Ashkenazi worked as the pharmaceutical company's CFO As Alphabet Inc. looks to fill a vacancy in its senior ranks, it's turning to a longtime
Google Poaches Eli Lilly Finance Chief Ashkenazi
By Colin Kellaher Google parent Alphabet has named Anat Ashkenazi chief financial officer, plucking the executive from drugmaker Eli Lilly. Write to Colin Kellaher at colin.kellaher@wsj.com
Analysis
Price Target
No Data
